Direct PeptidesProduct page includes use or preparation wordingIn stock
CJC-1295 with DAC · 5 mg × 10 vials
$889.00$17.78 / mg
Checked · 5 days ago
Lab report: Not linked
View product details (opens in a new tab)No commercial relationship
Research listings · Peptides
CJC-1295 with DAC research listings: prices and suppliers
Research materials and consumer products belong to different categories. A listing, laboratory report, or research-use label does not establish suitability for personal use.
We have no commercial relationship with suppliers on this page. Offers are sorted by price per mg; commission never changes the order.
Prices observed weekly · last check · How we check prices →
Lowest current at 5 mg × 10 vials$17.78 / mg · $889.00Direct Peptides · checked 5 days ago
Listings at 5 mg × 10 vials
| Supplier link | |||||||
|---|---|---|---|---|---|---|---|
| Direct PeptidesProduct page includes use or preparation wording | 5 mg × 10 vials | $889.00 | $17.78 / mg | In stock | 5 d ago | Not linked | View product details (opens in a new tab)No commercial relationship |
- Prices exclude shipping. A matching name does not verify the contents of a lot.
- Lab reports are vendor-reported, not independently authenticated. “Lab confirmed” means the issuing laboratory confirmed the report is theirs.
- Some suppliers’ product pages include use or preparation wording. We list their prices for comparison only; we do not endorse that wording, and nothing on this site is guidance on preparing or using these materials.
By size
Every package size we track for CJC-1295 with DAC. Current means seen in the last 8 days.
| 2 mg × 1 vial | $25.00 | $12.50 / mg | 1 / 2 | 1 |
|---|---|---|---|---|
| 5 mg × 1 vial | $52.00 | $10.40 / mg | 4 / 4 | 4 |
| 2 mg × 10 vials | — | — | 0 / 1 | 0 |
| 5 mg × 10 vials | $889.00 | $17.78 / mg | 1 / 1 | 1 |
Research context
From our own records, with the date each was last checked.
- FDA approval
- No approved drug product with this ingredient listed in Drugs@FDA (data updated 2026-11-02)Checked
- 503A / 503B compounding
- Not in any 503A category on FDA's 2026-05-14 list. FDA's safety-risk page lists "CJC-1295", without naming its forms, as formerly in category 2 with nominations withdrawnChecked
- Advisory committee (PCAC)
- PCAC voted against placing "CJC-1295 DAC (free base)" on the 503A list (0 yes, 13 no), and the same for the DAC acetate and DAC trifluoroacetate saltsChecked
- Rulemaking / enforcement
- No proposed or final rule found in the Federal Register (search on 2026-11-03); the only CJC-1295 match is FDA's 2024 PCAC meeting noticeChecked
- WADA
- S2.2.4 Growth hormone releasing factors: GHRH and its analogues · Prohibited at all times — in and out of competition (2026 list; unchanged in the 2027 list, in force from Jan 1, 2027)Checked
- Human studies
- 2 recorded
- Identity
- Formula C165H269N47O46 · MW 3647.2 g/mol · CAS 446262-90-4Sequence Modified GRF (1-29) with an albumin-binding lysine group (DAC) at the C-terminusSource record Checked
Read the guide:CJC-1295 and Ipamorelin: Reading the Research Separately
Identity noteThis record is CJC-1295 with DAC, the version tested in published human trials. Listings sold as CJC-1295 without DAC (modified GRF 1-29) are a different molecule and are tracked separately.
How we check prices · Offers are matched to our catalogue by an editor before they appear; a listing is not an endorsement.